Open AccessDrug correction of cardiac arrhythmias in patients with сoronary heart disease combined with mitral valve prolapse syndrome
Author(s) -
T. V. Naluzhna
Publication year - 2013
Publication title -
bukovinsʹkij medičnij vìsnik
Language(s) - English
Resource type - Journals
eISSN - 2413-0737
pISSN - 1684-7903
DOI - 10.24061/2413-0737.xvii.2.66.2013.74
Subject(s) - medicine , cardiology , mitral valve prolapse , atrial fibrillation , valvular heart disease , qt interval , sinus tachycardia , mitral valve
The paper presents data of cardiac arrhythmias in patients with coronary heart disease combined with the mitral valve prolapse syndrome. In these patients were dominated Sinus tachycardia, atrioventricular extrasystole, atrial fibrillation, paroxysmal tachycardia predominated in such patients. It has been proposed to include to the basic therapy these patients such preparations of magnesium, in particular, a domestic preparation – Rythmocor, taking into account the principal mechanisms of the development of arrhythmias. The antiarrhythmic, antiischemic, membranostabilizing action of the drug has been corroborated. A positive impact of Rhythmocor on the magnesium levels in the blood and a reduction of the duration of the interval QT has also been noteds correction of the arrhythmic syndrome has an important prognostic value in terms of reducing the risk of the onset of cardiac arrhythmias dangerous to life in patients with coronary heart disease, which occurs with the mitral valve prolapse syndrome.